Targeting angiopoietinâlike 3 in atherosclerosis: From bench to bedside
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.1111/dom.14450
Abstract: Atherosclerotic cardiovascular disease (ASCVD) is the largest cause of morbidity and mortality worldwide. Lipidâlowering therapies are the current major cornerstone of ASCVD management. Statins, ezetimibe, fibrates and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors effectively… read more here.
Keywords: atherosclerosis bench; like atherosclerosis; targeting angiopoietin; bench bedside ... See more keywords